Download PDF
Aktuelle Neurologie 2011; 38(10): 538-543
DOI: 10.1055/s-0031-1299773
Workshop
© Georg Thieme Verlag KG Stuttgart · New York

Indikationsstellung für invasive medikamentöse Therapien

Subcutaneous Apomorphine and Duodopa Infusion Therapy for Advanced Parkinson’s Disease
G. A. Fuchs
1   Parkinson-Klinik Wolfach
,
R. Hilker
2   Klinik für Neurologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt a. M.
,
M. Hahne
3   Neurologische Klinik, Bad Neustadt/Saale
,
M. Oechsner
4   HELIOS Klinik Zihlschacht, Neurologisches Rehabilitations Zentrum, Zihlschacht, Schweiz
,
H. Reichmann
5   Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
01 February 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Im Verlauf der Langzeitbehandlung des idiopathischen Parkinson-Syndroms entwickeln sich Wirkfluktuationen und Dyskinesien, aber auch nicht-motorische Störungen (autonome Dysfunktionen, psychiatrische Störungen), die sich mit den oralen Kombinationstherapien zunehmend schlechter ausgleichen lassen. Mit der kontinuierlichen subcutanen Apomorphin-Gabe und der duodenalen L-Dopa-Infusionstherapie (Duodopa-Pumpe) stehen 2 medikamentöse invasive, aber auch ökonomisch aufwändige alternative Therapieoptionen zur Verfügung. Nachfolgend werden die Differenzialindikationen beider Verfahren und ihr klinischer Stellenwert diskutiert.

Abstract

In the advanced stages of Parkinson’s disease, oral pharmacotherapy is often insufficient to obtain stable control of motor symptoms such as wearing-off phenomena, dyskinesias or non-motor symptoms. Invasive therapies like continuous subcutaneous infusion of apomorphine or the duodenal infusion of levodopa are promising options for the treatment of severe response fluctuations. In the present review the differential indications for these medical invasive treatments will be discussed.

Schlüsselwörter

Apomorphin - Duodopa - motorische Wirkfluktuationen - nicht-motorische Störungen - fortgeschrittenes idiopathisches Parkinson-Syndrom

Keywords

apomorphine - duodopa - motor flucutations - non-motor symptoms - advanced Parkinson’s disease
 

  • Literatur

  • 1 Poewe W, Wenning GK. The natural history of Parkinson’s disease. Ann Neurol 1998; 44: S1-S9
    CrossrefPubMedGoogle Scholar
  • 2 Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 2000; 123: 2297-2305
    CrossrefPubMedGoogle Scholar
  • 3 Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677-687
    CrossrefPubMedGoogle Scholar
  • 4 2. Deutschsprachiges Forum zur Therapie des fortgeschrittenen Morbus Parkinson. Kontinuierliche dopaminerge Stimulation beim fortgeschrittenen Morbus Parkinson. Hamburg, 29. Januar 2010
    PubMed
  • 5 Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112-1118
    CrossrefPubMedGoogle Scholar
  • 6 Defer GL, Widner H, Marié RM et al. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 1999; 14: 572-584
    CrossrefPubMedGoogle Scholar
  • 7 Diener H, Putzki N, Berlit P et al. Leitlinien für die Diagnostik und Therapie in der Neurologie. 4. überarbeitete Auflage ed. Stuttgart: Georg Thieme Verlag; 2008
    Google Scholar
  • 8 Ebersbach G, Hilker R. 1. Drug pumps and deep brain stimulation in therapy for Parkinson’s disease – Which therapy for which patients?. Akt Neurol 2011; 38 (Suppl S1) S39-S42
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Odin P, Honig H. Apomorphin- und Duodopa-Pumpentherapie bei Parkinson-Krankheit – Langzeiterfahrung und Vergleich. Psychopharmakotherapie, Sonderdruck 2007; 14: 96-100
    PubMedGoogle Scholar
  • 10 Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parlinson’s disease: longterm follow-up study of 64 patients. Mov Disord 2002; 17: 1235-1241
    CrossrefPubMedGoogle Scholar
  • 11 Reuter I. Nocturnal subcutaneous apomorphine infusion in Parkin­son’s disease and restless legs syndrome. Acta Neurol Scand 1999; 100: 163-167
    CrossrefPubMedGoogle Scholar
  • 12 Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord 2000; 15: 167-169
    CrossrefPubMedGoogle Scholar
  • 13 Di Rosa AE. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease. Neurol Sci 2003; 24: 174-175
    CrossrefPubMedGoogle Scholar
  • 14 Garcia Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson’s disease. Mov Disord 2006; 21: 727-728
    CrossrefPubMedGoogle Scholar
  • 15 Ceballos-Baumann A. Continuous subcutaneous infusion therapy with the apomorphine pump. Akt Neurol 2011; (Suppl S1) S17-S26
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Chaudhuri KR, Critchley Abott RJ. et al. Subcutaneous apomorphine for on-off oscillations in Parkinson’s disease. Lancet 1988; 2: 1260
    PubMedGoogle Scholar
  • 17 Hughes AJ, Bishop S, Kleedorfer B et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-170
    CrossrefPubMedGoogle Scholar
  • 18 Kanovsky P, Kubova D, Bares M et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002; 17: 188-191
    CrossrefPubMedGoogle Scholar
  • 19 Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: A prospective study using single-dose challenges. Mov Disord 2005; 20: 151-157
    CrossrefPubMedGoogle Scholar
  • 20 Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensedo B et al. Efficacy of long-term continuous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 2008; 23: 1130-1136
    CrossrefPubMedGoogle Scholar
  • 21 Naidu Y, Logishetty K, Martin A et al. Efficacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson’s disease. Park Rel Disord 2009; 15 (Suppl S2) S130 (P2.149)
    PubMedGoogle Scholar
  • 22 Chaudhuri KR, Abott RJ, Millac PA. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment. J Neurol Neurosurg Psychiatry 1990; 54: 372-373
    PubMedGoogle Scholar
  • 23 Ellis C. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism and Related disorders 1997; 3 (02) 103-107
    CrossrefPubMedGoogle Scholar
  • 24 Pietz K. Subcutaneous apomorphine in late stage Parkinson’s disease: A long-term follow-up. J Neurol Neurosurg Psychiatry 1998; 65: 709-716
    CrossrefPubMedGoogle Scholar
  • 25 Hagell P, Odin P, Shing M. Apomorphine bei Morbus Parkinson. 1. Auflage, ed. Bremen: UNI-MED-Verlag; 2005
    Google Scholar
  • 26 Martinez-Martin P, Todorova A, Henriksen T et al. The motor and nonmotor efficacy of subcutaneous apomorphine infusion in chronic advanced PD compared to Parkinson’s patients on conventional therapy. A “real life” study. Mov Disord 2010; 25 (Suppl 2) S421
    CrossrefPubMedGoogle Scholar
  • 27 Honig H, Odin P, Chaudhuri KR. Effect of apomorphine on non-motor symptoms in Parkinson’s disease. Akt Neurol 2011; 38 (Suppl S1) S34-S38
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 O’Sullivan JD, Hughes AJ. Apomorphine induced penile erections in Parkinson’s disease. Mov Disord 1998; 13: 536-539
    CrossrefPubMedGoogle Scholar
  • 29 Dula E, Bukofzer S Perdok et al. Double blind crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-564
    CrossrefPubMedGoogle Scholar
  • 30 Klos KJ. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Park Relat Disord 2005; 11: 381-386
    CrossrefPubMedGoogle Scholar
  • 31 Homann CN, Wenzel K, Suppan K et al. Sleep attacks in patients taking dopamine agonists: review. BMJ. 2002 324. 1483-1487
    PubMedGoogle Scholar
  • 32 O’Sullivan JD, Lees AJ. Use of apomorphine in Parkinson’s disease. Hosp Med 1999; 60: 816-820
    PubMedGoogle Scholar
  • 33 Lees AJ, Richardson C, Turner K. Treatment of Parkinson’s disease with apomorphine. Shared guidelines. 3rd edition London: UCL Hospitals NHS Trust; 1998
    Google Scholar
  • 34 Todd A, James CA. Apomorphine nodules in Parkinson’s disease: best practice considerations. Br J Community Nurs 2008; 13: 457-463
    PubMedGoogle Scholar
  • 35 Poltawski L, Edwards H, Todd A et al. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord 2009; 24: 115-118
    CrossrefPubMedGoogle Scholar
  • 36 Blickpunkt Medizin . 50 Jahre L-Dopa: Von der Tablette zur duodenalen Infusion; 3. Deutschsprachiges Forum zur Therapie des fortgeschrittenen Morbus Parkinson, Innsbruck, 28. Januar 2011. Akt Neurol 2011;
    PubMedGoogle Scholar
  • 37 Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 2005; 20: 151-157
    CrossrefPubMedGoogle Scholar
  • 38 Antonini A, Isaias IU, Canesi M et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-1149
    CrossrefPubMedGoogle Scholar
  • 39 Antonini A. Continuous dopaminergic stimulation – from theory to clinical practice. Parkinsonism Relat Disord 2007; 13 (Suppl) S24-S28
    CrossrefPubMedGoogle Scholar
  • 40 Eggert K, Schrader C, Hahn M et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008; 31: 151-166
    CrossrefPubMedGoogle Scholar
  • 41 Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on non-motor symptoms and quality of life. Mov Disord 2009; 24: 1468-1474
    CrossrefPubMedGoogle Scholar
  • 42 Santos-Garcia D, Sanjurjo LF, Macias M et al. Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand DOI: 10.1111/j.1600-0404.2011.01523.x,. 2011;
    PubMedGoogle Scholar
  • 43 Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 2009; 24: 993-1000
    CrossrefPubMedGoogle Scholar
  • 44 Nyholm D, Lewander T, Johansson A et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 31: 63-73
    CrossrefPubMedGoogle Scholar
  • 45 Klostermann F. Benefit from jejunal levodopa in a patient with apomorphine pump. J Neurol 2011; 258: 311-312
    PubMedGoogle Scholar
  • 46 Nyholm D, Jansson R, Willows T et al. Long-term 24-hour duodenal levodopa infusion – outcome and dose requirements. Neurology 2005; 65: 1506-1507
    CrossrefPubMedGoogle Scholar
  • 47 Manca D, Cossu G, Murgia D et al. Reversible encephalopathy and axonal neuropathy in Parkinson’s Disease during duodopa therapy. Mov Disord 2009; 24: 2293-2294
    CrossrefPubMedGoogle Scholar
  • 48 Santos-Garcia D, Macias M, Llaneza M et al. Serum vitamin B12 and folate levels in Parkinson’s Disease patients treated with duodenal levodopa infusion. Mov Disord 2011; 26: 558-559
    CrossrefPubMedGoogle Scholar
  • 49 Elia A, Dollenz C, Soliveri P et al. Motor features and response to oral levodopa in patients with Parkinson’s Disease under continuous dopaminergic infusion or deep brain stimulation. Euro J Neurol DOI: 10.1111/j.1468-1331.2011.03437.x,. 2011;
    PubMedGoogle Scholar
  • 50 Hilker R, Antonini A, Odin P. What is the best treatment for fluctuating Parkinson’s Disease: continuous drug delivery or deep brain stimula­tion of the subthalamic nucleus?. J Neural Transm 2011; 118: 907-914
    CrossrefPubMedGoogle Scholar